{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:32:55Z","timestamp":1793338375002,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cgh.2026.09.034","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:04:31Z","timestamp":1790867071000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Artificial Intelligence in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease: A 3-Level Framework Across Clinical, Health System, and Policy Decisions"],"prefix":"10.1016","author":[{"given":"Markos","family":"Kalligeros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Papatheodoridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.09.034_bib1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000829","article-title":"Low awareness of MASLD among U.S. adults: trends from NHANES 2017-2023","volume":"9","author":"Alp","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2026.09.034_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11606-024-08955-9","article-title":"Identifying and linking patients at risk for MASLD with advanced fibrosis to care in primary care","volume":"40","author":"Xiao","year":"2025","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.cgh.2026.09.034_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.034_bib5","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.034_bib6","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.cgh.2026.03.030","article-title":"Updated global consensus recommendations for risk stratification, treatment initiation, and response monitoring in metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Younossi","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib7","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jare.2025.08.042","article-title":"Application of machine learning and deep learning in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"83","author":"Zhang","year":"2026","journal-title":"J Adv Res"},{"key":"10.1016\/j.cgh.2026.09.034_bib8","first-page":"36","article-title":"Disease progression for histologic diagnosis of metabolic dysfunction-associated steatotic liver disease in the real-world: a nationwide US study","volume":"43","author":"Zhang","year":"2025","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2026.09.034_bib9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.034_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jhep.2025.09.019","article-title":"Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials","volume":"84","author":"Lackner","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54904-6","article-title":"Deep learning enables pathologist-like scoring of NASH models","volume":"9","author":"Heinemann","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2026.09.034_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23905-3","article-title":"Deep learning-based quantification of NAFLD\/NASH progression in human liver biopsies","volume":"12","author":"Heinemann","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2026.09.034_bib13","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.034_bib14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/HEP.0000000000001617","article-title":"Predictors of fibrosis, clinical events, and mortality in MASLD: data from the Global-MASLD study","volume":"84","author":"Younossi","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.034_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/diagnostics16020261","article-title":"Artificial intelligence for fibrosis diagnosis in metabolic-dysfunction-associated steatotic liver disease: a systematic review","volume":"16","author":"Souza","year":"2026","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cgh.2026.09.034_bib16","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1097\/HEP.0000000000001121","article-title":"Disparities in screening and risk stratification for Hispanic adults with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Tincopa","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.034_bib17","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.cgh.2026.01.016","article-title":"Diagnostic accuracy of noninvasive tests for metabolic dysfunction-associated steatotic liver disease across age, type 2 diabetes, and obesity subgroups: a multinational study","volume":"24","author":"Younossi","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14309\/ajg.0000000000003432","article-title":"ALADDIN: a machine learning approach to enhance the prediction of significant fibrosis or higher in metabolic dysfunction-associated steatotic liver disease","volume":"121","author":"Alkhouri","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.034_bib19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.32655","article-title":"Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis","volume":"77","author":"Chang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.034_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jhbp.972","article-title":"Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD","volume":"28","author":"Feng","year":"2021","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.cgh.2026.09.034_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050722","article-title":"Revolutionizing MASLD: how artificial intelligence is shaping the future of liver care","volume":"17","author":"Pugliese","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cgh.2026.09.034_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2025.100765","article-title":"Development of a neural network to detect hepatic steatosis in metabolic dysfunction-associated steatotic liver disease","volume":"5","author":"Hirooka","year":"2026","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.cgh.2026.09.034_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70416","article-title":"Machine learning models for screening steatosis in MASLD: an international validation study","volume":"45","author":"Ye","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2026.09.034_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.103438","article-title":"A simple laboratory-based machine learning model accurately predicts advanced liver fibrosis in metabolic dysfunction-associated steatotic liver disease patients","volume":"16","author":"Sharma","year":"2026","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/dom.70168","article-title":"An interpretable machine learning model for predicting metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes","volume":"28","author":"Zhou","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cgh.2026.09.034_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.31750","article-title":"A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH","volume":"74","author":"Taylor-Weiner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.034_bib27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/kjm2.12850","article-title":"Development of a diagnostic support system for the fibrosis of nonalcoholic fatty liver disease using artificial intelligence and deep learning","volume":"40","author":"Preechathammawong","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.cgh.2026.09.034_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100377","article-title":"An end-to-end platform for digital pathology using hyperspectral autofluorescence microscopy and deep learning-based virtual histology","volume":"37","author":"McNeil","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cgh.2026.09.034_bib29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/cts.13235","article-title":"Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH","volume":"15","author":"Mollerhoj","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.cgh.2026.09.034_bib30","article-title":"The relationship between non-invasive tests and digital pathology for quantifying liver fibrosis in MASLD","volume":"15","author":"Wei","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.cgh.2026.09.034_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2023.107932","article-title":"Application of artificial intelligence techniques for non-alcoholic fatty liver disease diagnosis: a systematic review (2005-2023)","volume":"244","author":"Zamanian","year":"2024","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.cgh.2026.09.034_bib32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","article-title":"The utility of radiological imaging in nonalcoholic fatty liver disease","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterogy"},{"key":"10.1016\/j.cgh.2026.09.034_bib33","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1007\/s00261-025-05309-9","article-title":"Deep learning for non-invasive detection of steatosis and fibrosis in MASLD: a multicenter study with a new fibroscan-labelled ultrasound dataset","volume":"51","author":"Bose","year":"2026","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.cgh.2026.09.034_bib34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.cgh.2026.09.034_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aeb5665","article-title":"Cross-trait genomic modeling reveals the polygenic architecture and systemic impact of MASLD","volume":"12","author":"Du","year":"2026","journal-title":"Sci Adv"},{"key":"10.1016\/j.cgh.2026.09.034_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12876-026-04624-9","article-title":"Genome-wide association and integrative analyses of relative handgrip strength identify polygenic determinants of gastrointestinal disorder susceptibility","volume":"26","author":"Jiang","year":"2026","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.034_bib37","doi-asserted-by":"crossref","first-page":"9494","DOI":"10.62347\/KPGF8790","article-title":"A set of downregulated pleiotropic genes are possible multi-omics biomarkers underlying the irritable bowel syndrome-non-alcoholic fatty liver disease comorbidity","volume":"17","author":"Hong","year":"2025","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.cgh.2026.09.034_bib38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41746-026-02352-8","article-title":"Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH","volume":"9","author":"Wen","year":"2026","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.cgh.2026.09.034_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2025.103184","article-title":"Artificial intelligence for predictive diagnostics, prognosis, and decision support in MASLD, hepatocellular carcinoma, and digital pathology","volume":"16","author":"Dunn","year":"2026","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib40","article-title":"Artificial intelligence as a ploy to delve into the intricate link between genetics and mitochondria in patients with MASLD","volume":"7","author":"Longo","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2026.09.034_bib41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jgh3.12716","article-title":"Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis","volume":"6","author":"Ghandian","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.cgh.2026.09.034_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.gastha.2023.09.004","article-title":"Identification of fast progressors among patients with nonalcoholic steatohepatitis using machine learning","volume":"3","author":"Schattenberg","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.cgh.2026.09.034_bib43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/a-2435-2091","article-title":"Patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease","volume":"45","author":"Barbera","year":"2025","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2026.09.034_bib44","article-title":"Proteomic signatures reflect effects of semaglutide treatment for MASH","volume":"7","author":"Schattenberg","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2026.09.034_bib45","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2025.04.035","article-title":"High inherited risk predicts age-associated increases in fibrosis in patients with MASLD","volume":"83","author":"Diaz","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib46","first-page":"631","article-title":"The emerging challenge of non-cirrhotic MASLD-related hepatocellular carcinoma: etiology, immunopathology, and precision oncology","volume":"15","author":"Liu","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.cgh.2026.09.034_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21019","article-title":"Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Rodriguez","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cgh.2026.09.034_bib48","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2025.06.025","article-title":"A novel risk prediction model for hepatocellular carcinoma in MASLD: a multinational, multicenter cohort study","volume":"24","author":"Chun","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib49","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1136\/gutjnl-2025-334981","article-title":"Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"Lai","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.09.034_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2017.07.015","article-title":"Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study","volume":"61","author":"Barritt","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.cgh.2026.09.034_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236021","article-title":"Using machine learning algorithms to review computed tomography scans and assess risk for cardiovascular disease: retrospective analysis from the National Lung Screening Trial (NLST)","volume":"15","author":"Stemmer","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2026.09.034_bib52","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2026.09.034_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2468-1253(25)00376-0","article-title":"Binge drinking, metabolic dysfunction, and the spectrum of steatotic liver disease in the USA: a cross-sectional and longitudinal analysis","volume":"11","author":"Younossi","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib54","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.14309\/ajg.0000000000003321","article-title":"Identifying metabolic dysfunction-associated steatotic liver disease using natural Language processing in a US national cohort","volume":"120","author":"John","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.034_bib55","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jhep.2025.05.026","article-title":"Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles","volume":"83","author":"Liu","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib56","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.18506","article-title":"Head-to-Head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study","volume":"61","author":"Tavaglione","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.09.034_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0334715","article-title":"Use of machine learning for early prediction of short-term mortality in veterans with metabolic dysfunction-associated steatotic liver disease","volume":"20","author":"Frey","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2026.09.034_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067203","article-title":"Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III","volume":"12","author":"Carrillo-Larco","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.cgh.2026.09.034_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000834","article-title":"Development of an AI algorithm for early identification of MASLD in the electronic health record","volume":"9","author":"Stuart","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2026.09.034_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102149","article-title":"Large-scale identification of undiagnosed hepatic steatosis using natural language processing","volume":"62","author":"Schneider","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cgh.2026.09.034_bib61","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10620-025-09539-1","article-title":"Large Language models can identify the presence of MASH and extract VCTE measurements from unstructured documentation","volume":"71","author":"Far","year":"2026","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.09.034_bib62","doi-asserted-by":"crossref","first-page":"916","DOI":"10.14309\/ajg.0000000000003830","article-title":"Harnessing natural Language processing to identify documentation of serious illness communication for patients with decompensated cirrhosis","volume":"121","author":"Smith","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.034_bib63","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2023.12.019","article-title":"A comparison of a large Language model vs manual chart review for the extraction of data elements from the electronic health record","volume":"166","author":"Ge","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.034_bib64","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.15891","article-title":"Using GPT-4 for LI-RADS feature extraction and categorization with multilingual free-text reports","volume":"44","author":"Gu","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2026.09.034_bib65","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41575-025-01108-1","article-title":"Large language models for clinical decision support in gastroenterology and hepatology","volume":"22","author":"Wiest","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16119","article-title":"Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2026.09.034_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2025.101789","article-title":"Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)","volume":"30","author":"Younossi","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/liv.15730","article-title":"A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies","volume":"44","author":"Forlano","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2026.09.034_bib69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jhep.2025.01.009","article-title":"Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States","volume":"83","author":"Wallace","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12032-025-03157-7","article-title":"Ethical challenges and governance of artificial intelligence in hepatocellular carcinoma management: Wan DL et al. Ethical considerations in AI for hepatocellular carcinoma","volume":"43","author":"Wan","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.cgh.2026.09.034_bib71","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12933-024-02409-6","article-title":"Two-week continuous glucose monitoring-derived metrics and degree of hepatic steatosis: a cross-sectional study among Chinese middle-aged and elderly participants","volume":"23","author":"Zhong","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cgh.2026.09.034_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101684","article-title":"Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study","volume":"51","author":"Mantovani","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cgh.2026.09.034_bib73","article-title":"Validation of the chronic liver disease questionnaire for MASH (CLDQ-MASH)","volume":"7","author":"Younossi","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2026.09.034_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70311","article-title":"Managing MASLD through preventive hepatology: integrating policy reform, public health and personalised care","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2026.09.034_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cgh.2026.09.034_bib76","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12944-025-02750-z","article-title":"The burden of NAFLD (now referred to as MASLD)-related chronic liver disease and cirrhosis from 1990 to 2021 with projections to 2036: a comparative study of global China the United States and India","volume":"24","author":"Zeng","year":"2025","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.cgh.2026.09.034_bib77","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: a review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2026.09.034_bib78","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American diabetes association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cgh.2026.09.034_bib79","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1007\/s10620-026-09811-y","article-title":"AI-Based screening for at-risk MASLD and advanced fibrosis in the US population: a cost-effectiveness analysis","volume":"71","author":"Njei","year":"2026","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2026.09.034_bib81","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/gutjnl-2021-326271","article-title":"Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity","volume":"71","author":"Uche-Anya","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.09.034_bib82","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1007\/s00125-026-06726-1","article-title":"MASLD prevalence, incidence and global aspects","volume":"69","author":"Wild","year":"2026","journal-title":"Diabetologia"},{"key":"10.1016\/j.cgh.2026.09.034_bib83","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2468-1253(25)00300-0","article-title":"Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study","volume":"11","author":"Lazarus","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib84","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11154-021-09681-x","article-title":"Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : a systematic review","volume":"23","author":"Li","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.cgh.2026.09.034_bib85","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i24.108021","article-title":"Revolutionizing gastroenterology and hepatology with artificial intelligence: from precision diagnosis to equitable healthcare through interdisciplinary practice","volume":"31","author":"Chen","year":"2025","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.034_bib86","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.14309\/ajg.0000000000003421","article-title":"Social determinants of health associated with metabolic dysfunction-associated steatotic liver disease prevalence and severity: a systematic review and meta-analysis","volume":"120","author":"Abu-Rumaileh","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.034_bib87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12929-025-01131-z","article-title":"Impact of large language model (ChatGPT) in healthcare: an umbrella review and evidence synthesis","volume":"32","author":"Iqbal","year":"2025","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.cgh.2026.09.034_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0317929","article-title":"Assessment of ChatGPT-generated medical Arabic responses for patients with metabolic dysfunction-associated steatotic liver disease","volume":"20","author":"Alqahtani","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2026.09.034_bib89","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","article-title":"Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease","volume":"82","author":"Arab","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib90","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2468-1253(25)00187-6","article-title":"Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study","volume":"10","author":"Torp","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib91","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2025.05.030","article-title":"Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification","volume":"83","author":"Tavaglione","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.cgh.2026.09.034_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2026.09.034_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526007378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526007378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:14:49Z","timestamp":1793337289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526007378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":92,"alternative-id":["S1542356526007378"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.09.034","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artificial Intelligence in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease: A 3-Level Framework Across Clinical, Health System, and Policy Decisions","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}